ArticleScientific reports2026
Lycium barbarum polysaccharide inhibits Hcy-induced vascular smooth muscle cells migration and invasion via upregulation of KLF4.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study examined the potential protective effects of Lycium barbarum polysaccharide (LBP) in opposing homocysteine (Hcy)-triggered vascular smooth muscle cells (VSMCs) migration and invasion. Additionally, we examined how Krüppel-like factor 4 (KLF4) participates in the underlying molecular mechanism. Primary human umbilical vein VSMCs were treated with Hcy (100 µmol/L) and divided into five groups: Control, Hcy (100 µmol/L), Hcy + 400 mg/L LBP, Hcy + 600 mg/L LBP, Hcy + 800 mg/L LBP. Cell migration was assessed by scratch assay to screen the optimal drug intervention concentration. KLF4 expression was analyzed via Western blot. Subsequently, cells were treated with Hcy+KLF4 agonist (APTO-235, AP), Hcy+KLF4 inhibitor (Kenpaullone, Ken), and Hcy + LBP+AP. Cell migration and invasion capacities were assessed via scratch assay and Transwell invasion assay. In comparison to the Control group, Hcy notably promoted VSMC migration and invasion and downregulated KLF4 expression. Both the Hcy + 600 mg/L LBP group and the Hcy + AP group exhibited reduced migration/invasion (P < 0.01 vs. Hcy) and upregulated KLF4. Conversely, Hcy + Ken increased migration/invasion and suppressed KLF4. Notably, Hcy + LBP+AP showed the strongest inhibition of migration/invasion and the highest KLF4 upregulation (P < 0.01 vs. Hcy + AP or Hcy + 600 mg/L LBP). LBP inhibits Hcy-induced VSMCs migration and invasion by upregulating KLF4, with synergistic effects observed upon KLF4 agonist co-treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.